NZ536412A - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same - Google Patents

Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Info

Publication number
NZ536412A
NZ536412A NZ536412A NZ53641203A NZ536412A NZ 536412 A NZ536412 A NZ 536412A NZ 536412 A NZ536412 A NZ 536412A NZ 53641203 A NZ53641203 A NZ 53641203A NZ 536412 A NZ536412 A NZ 536412A
Authority
NZ
New Zealand
Prior art keywords
framework
antibody
sequences
sequence
protein
Prior art date
Application number
NZ536412A
Other languages
English (en)
Inventor
Kathrin Tissot
Stefan Ewert
Der Maur Adrian Auf
Alcide Barberis
Dominik Escher
Original Assignee
Esbatech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Ag filed Critical Esbatech Ag
Publication of NZ536412A publication Critical patent/NZ536412A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ536412A 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same NZ536412A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US43825603P 2003-01-03 2003-01-03
PCT/EP2003/005324 WO2003097697A2 (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Publications (1)

Publication Number Publication Date
NZ536412A true NZ536412A (en) 2008-10-31

Family

ID=29553590

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ536412A NZ536412A (en) 2002-05-22 2003-05-21 Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Country Status (14)

Country Link
US (5) US8853362B2 (OSRAM)
EP (5) EP2314622B1 (OSRAM)
JP (10) JP2006508638A (OSRAM)
CN (4) CN105175535A (OSRAM)
AU (2) AU2003238370B2 (OSRAM)
CA (2) CA2483285C (OSRAM)
CY (1) CY1114225T1 (OSRAM)
DK (2) DK1506236T3 (OSRAM)
ES (3) ES2656427T3 (OSRAM)
HU (1) HUE048922T2 (OSRAM)
NZ (1) NZ536412A (OSRAM)
PT (2) PT2332989E (OSRAM)
SI (2) SI2332989T1 (OSRAM)
WO (1) WO2003097697A2 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
EP2368992A3 (en) 2005-03-25 2012-03-14 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
AU2007246144B2 (en) 2006-04-28 2012-12-06 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
ES2820837T3 (es) 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
BRPI0813287A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Planejamento e otimização baseados na sequência de anticorpos de cadeia única
CA2689941C (en) * 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
SG188136A1 (en) 2007-09-13 2013-03-28 Delenex Therapeutics Ag HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
PT2752428T (pt) * 2008-06-25 2020-02-14 Novartis Ag Humanização de anticorpos de coelho com utilização de um framework de anticorpos universal
MX345395B (es) * 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
MX2011000074A (es) 2008-06-25 2011-02-24 Esbatech Alcon Biomed Res Unit Optimizacion de solubilidad de inmuno-aglutinantes.
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
KR101737466B1 (ko) 2008-06-25 2017-05-18 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
EP3964526A1 (en) 2008-06-25 2022-03-09 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
WO2010003268A2 (en) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
SG10201408247SA (en) * 2009-02-24 2015-02-27 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8399624B1 (en) 2009-06-25 2013-03-19 Esbatech, An Alcon Biomedical Research Unit Llc Acceptor framework for CDR grafting
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
AU2012325232B2 (en) 2011-10-20 2017-08-31 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
CN106986934B (zh) * 2012-08-22 2021-09-14 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
JP6333271B2 (ja) 2012-11-05 2018-06-06 セル メディカ スイッツァランド アーゲー ＩＬ−１βへの結合メンバー
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
JP2016506974A (ja) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
RU2015139890A (ru) * 2013-02-20 2017-03-27 ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи Акцепторный каркасный участок для пересадки cdr
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7017015B2 (ja) 2015-10-13 2022-02-08 エウレカ セラピューティクス インコーポレイテッド ヒトｃｄ１９に特異的な抗体剤及びその使用
RU2767209C2 (ru) 2015-10-23 2022-03-16 Еурека Терапьютикс, Инк. Химерные конструкции антитело/т-клеточный рецептор и их применения
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
BR112018067696A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag membros de ligação à pd-l1
IL265484B1 (en) 2016-09-21 2025-09-01 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2019199941A1 (en) * 2018-04-10 2019-10-17 Northwestern University Extracellular vesicles comprising targeting affinity domain-based membrane proteins
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
AU2021308712B2 (en) 2020-07-16 2025-10-09 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20230154994A (ko) 2021-03-10 2023-11-09 마빌론 아게 Tdp-43에 대한 항체 및 이의 용도
EP4469081A1 (en) 2022-01-24 2024-12-04 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6706484B1 (en) * 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
AU3587599A (en) 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Also Published As

Publication number Publication date
US8853362B2 (en) 2014-10-07
CN102093477B (zh) 2014-02-26
AU2010202634A1 (en) 2010-07-15
JP2017201990A (ja) 2017-11-16
ES2399617T3 (es) 2013-04-02
JP2015214583A (ja) 2015-12-03
DK2332989T3 (en) 2015-05-11
SI2332989T1 (sl) 2015-06-30
WO2003097697A2 (en) 2003-11-27
JP2019058191A (ja) 2019-04-18
US20150057191A1 (en) 2015-02-26
US20200165322A1 (en) 2020-05-28
AU2003238370B2 (en) 2010-04-29
EP2947095B1 (en) 2019-10-02
EP2314622A1 (en) 2011-04-27
EP1506236A2 (en) 2005-02-16
US20190119361A1 (en) 2019-04-25
US20170107272A1 (en) 2017-04-20
ES2537104T3 (es) 2015-06-02
AU2003238370A1 (en) 2003-12-02
EP2332989A1 (en) 2011-06-15
JP2013256533A (ja) 2013-12-26
EP2947095A1 (en) 2015-11-25
PT2332989E (pt) 2015-08-05
US10125186B2 (en) 2018-11-13
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
EP3656787A1 (en) 2020-05-27
HK1217712A1 (en) 2017-01-20
CA2867542C (en) 2020-04-14
CN103739706B (zh) 2015-11-18
JP2013078343A (ja) 2013-05-02
HK1071378A1 (en) 2005-07-15
EP2314622B1 (en) 2017-10-18
CA2867542A1 (en) 2003-11-27
CN103739706A (zh) 2014-04-23
CA2483285C (en) 2015-01-27
EP2332989B1 (en) 2015-04-01
JP2006508638A (ja) 2006-03-16
HUE048922T2 (hu) 2020-09-28
US20060035320A1 (en) 2006-02-16
CN102093477A (zh) 2011-06-15
JP2012228272A (ja) 2012-11-22
ES2656427T3 (es) 2018-02-27
JP6100544B2 (ja) 2017-03-22
JP6918033B2 (ja) 2021-08-11
US10570190B2 (en) 2020-02-25
CN1662556B (zh) 2013-05-01
AU2010202634B2 (en) 2012-08-23
CN1662556A (zh) 2005-08-31
JP6261136B2 (ja) 2018-01-17
CN105175535A (zh) 2015-12-23
EP1506236B1 (en) 2013-01-23
HK1152320A1 (en) 2012-02-24
CY1114225T1 (el) 2016-08-31
JP2020171286A (ja) 2020-10-22
WO2003097697A3 (en) 2004-12-09
CA2483285A1 (en) 2003-11-27
JP6075836B2 (ja) 2017-02-08
JP2015227372A (ja) 2015-12-17
DK1506236T3 (da) 2013-03-04
JP2010187678A (ja) 2010-09-02
PT1506236E (pt) 2013-03-27

Similar Documents

Publication Publication Date Title
US10570190B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2015202410B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2013203288B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1217712B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1071378B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2012211497B2 (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804A (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1151804B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
HK1152320B (en) Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 MAY 2016 BY CPA GLOBAL

Effective date: 20130405

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2017 BY CPA GLOBAL

Effective date: 20160409

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2018 BY CPA GLOBAL

Effective date: 20170418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2019 BY CPA GLOBAL

Effective date: 20180419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2020 BY CPA GLOBAL

Effective date: 20190418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2021 BY CPA GLOBAL

Effective date: 20200416

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2022 BY CPA GLOBAL

Effective date: 20210422

ASS Change of ownership

Owner name: NOVARTIS AG, CH

Effective date: 20211208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAY 2023 BY CPA GLOBAL

Effective date: 20220421

EXPY Patent expired